Assessing Prognosis in Metastatic Pancreatic Cancer by the Serum Tumor Marker CA 19-9: Pretreatment Levels or Kinetics During Chemotherapy?

Oncology Research and Treatment - Switzerland
doi 10.1159/000097764
Full Text
Abstract

Available in full text

Date
Authors
Publisher

S. Karger AG

Related search

Estimating Prognosis and Palliation Based on Tumour Marker CA 19-9 and Quality of Life Indicators in Patients With Advanced Pancreatic Cancer Receiving Chemotherapy

British Journal of Cancer
Cancer ResearchOncology
2010English

Highly Sensitive Plasmonic Detection of the Pancreatic Cancer Biomarker CA 19-9

Scientific Reports
Multidisciplinary
2017English

Prognostic and Therapeutic Significance of Carbohydrate Antigen 19-9 as Tumor Marker in Patients With Pancreatic Cancer

Oncology
MedicineCancer ResearchOncology
2006English

Increased Serum CA 19-9 Antibodies in Sjogren's Syndrome.

Postgraduate Medical Journal
Medicine
1998English

Monitoring Ovarian Carcinoma With CA 125, CA 19–9, CA 15–3 and CEA in Serum, Ascites and Tumor Tissue

Journal of Cancer Research and Clinical Oncology
MedicineCancer ResearchOncology
1986English

Type 2 Dıabetes Mellıtus and CA 19-9 Levels

World Journal of Gastroenterology
MedicineGastroenterology
2007English

Elevated Serum CA 19-9 Levels in Dermoid Cyst: A Predictor of Ovarian Torsion and Tissue Necrosis?

International Journal of Reproduction, Contraception, Obstetrics and Gynecology
2019English

Benign Hydronephrosis and Elevated of Serum Levels of Carbohydrate Antigen CA 19-9: A Case Report

American Journal of Case Reports
Medicine
2016English

Levels of CEA and Ca 19 - 9 in the Sera and Peritoneal Cavity in Patients With Gastric and Pancreatic Cancers

Acta Cirurgica Brasileira
Surgery
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy